HLS Therapeutics Inc.

TSX:HLS Stock Report

Market Cap: CA$118.0m

HLS Therapeutics Valuation

Is HLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLS (CA$3.84) is trading below our estimate of fair value (CA$23.86)

Significantly Below Fair Value: HLS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLS?

Key metric: As HLS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HLS. This is calculated by dividing HLS's market cap by their current revenue.
What is HLS's PS Ratio?
PS Ratio1.5x
SalesUS$56.94m
Market CapUS$82.08m

Price to Sales Ratio vs Peers

How does HLS's PS Ratio compare to its peers?

The above table shows the PS ratio for HLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
RX BioSyent
3.9x12.9%CA$132.3m
PLTH Planet 13 Holdings
1.1x41.2%CA$172.3m
VREO Vireo Growth
1.3x3.4%CA$179.6m
AYR.A Ayr Wellness
0.1x4.0%CA$72.9m
HLS HLS Therapeutics
1.5x8.6%CA$118.0m

Price-To-Sales vs Peers: HLS is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does HLS's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.1x4.0%US$50.72m
IAN iAnthus Capital Holdings
0.1xn/aUS$23.22m
TIUM.U Cansortium
0.2xn/aUS$21.05m
RWB Red White & Bloom Brands
0.2xn/aUS$13.09m
HLS 1.5xIndustry Avg. 0.8xNo. of Companies27PS012345+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HLS is expensive based on its Price-To-Sales Ratio (1.5x) compared to the Canadian Pharmaceuticals industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is HLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: HLS is expensive based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$3.84
CA$5.92
+54.3%
41.4%CA$9.55CA$3.51n/a5
Dec ’25CA$3.61
CA$5.92
+64.1%
41.4%CA$9.55CA$3.51n/a5
Nov ’25CA$3.25
CA$6.08
+87.1%
45.8%CA$9.55CA$3.27n/a4
Oct ’25CA$3.66
CA$5.64
+54.2%
46.3%CA$9.51CA$3.25n/a5
Sep ’25CA$3.32
CA$5.64
+70.0%
46.3%CA$9.51CA$3.25n/a5
Aug ’25CA$3.14
CA$5.93
+88.8%
41.6%CA$9.66CA$3.75n/a5
Jul ’25CA$3.35
CA$5.85
+74.6%
41.4%CA$9.51CA$3.75n/a5
Jun ’25CA$3.72
CA$5.85
+57.3%
41.4%CA$9.51CA$3.75n/a5
May ’25CA$4.65
CA$6.83
+47.0%
39.0%CA$10.70CA$4.23n/a5
Apr ’25CA$4.06
CA$7.23
+78.2%
37.4%CA$10.51CA$4.16n/a4
Mar ’25CA$4.20
CA$7.55
+79.8%
31.0%CA$10.25CA$4.35n/a4
Feb ’25CA$4.15
CA$7.18
+73.1%
30.7%CA$10.21CA$5.02n/a3
Jan ’25CA$3.95
CA$8.16
+106.6%
31.7%CA$11.19CA$5.00n/a4
Dec ’24CA$3.44
CA$8.37
+143.4%
32.3%CA$11.53CA$5.01CA$3.614
Nov ’24CA$4.93
CA$12.25
+148.4%
15.5%CA$14.27CA$9.20CA$3.254
Oct ’24CA$5.00
CA$12.11
+142.1%
15.5%CA$14.06CA$9.06CA$3.664
Sep ’24CA$4.67
CA$12.83
+174.7%
17.6%CA$15.02CA$9.09CA$3.324
Aug ’24CA$6.10
CA$13.86
+127.2%
22.9%CA$17.86CA$8.99CA$3.144
Jul ’24CA$5.76
CA$15.79
+174.1%
27.5%CA$22.71CA$9.75CA$3.355
Jun ’24CA$4.34
CA$16.71
+285.1%
25.9%CA$23.40CA$10.05CA$3.725
May ’24CA$5.51
CA$17.87
+224.4%
15.9%CA$23.12CA$14.61CA$4.655
Apr ’24CA$6.30
CA$18.23
+189.4%
16.0%CA$23.71CA$14.98CA$4.065
Mar ’24CA$8.53
CA$23.31
+173.3%
6.7%CA$25.97CA$21.69CA$4.205
Feb ’24CA$9.59
CA$23.22
+142.1%
6.6%CA$25.85CA$21.61CA$4.155
Jan ’24CA$9.83
CA$23.66
+140.7%
5.9%CA$25.92CA$22.16CA$3.955
Dec ’23CA$9.95
CA$23.34
+134.5%
6.0%CA$25.63CA$21.84CA$3.445

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 05:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HLS Therapeutics Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity
George UlybyshevClarus Securities Inc.